Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk Diffuse Large B-cell Lymphoma to BCL2 inhibition.

Autor: Dey J; Presage Biosciences, Inc, Seattle, WA, USA., Deckwerth TL; Presage Biosciences, Inc, Seattle, WA, USA., Kerwin WS; Presage Biosciences, Inc, Seattle, WA, USA., Casalini JR; Presage Biosciences, Inc, Seattle, WA, USA., Merrell AJ; Presage Biosciences, Inc, Seattle, WA, USA., Grenley MO; Presage Biosciences, Inc, Seattle, WA, USA., Burns C; Presage Biosciences, Inc, Seattle, WA, USA., Ditzler SH; Presage Biosciences, Inc, Seattle, WA, USA., Dixon CP; Presage Biosciences, Inc, Seattle, WA, USA., Beirne E; Presage Biosciences, Inc, Seattle, WA, USA., Gillespie KC; Presage Biosciences, Inc, Seattle, WA, USA., Kleinman EF; Edward F. Kleinman LLC, Pawcatuck, CT, USA., Klinghoffer RA; Presage Biosciences, Inc, Seattle, WA, USA. rich.klinghoffer@presagebio.com.

Publikováno v: Scientific reports [Sci Rep] 2017 Dec 21; Vol. 7 (1), pp. 18007. Date of Electronic Publication: 2017 Dec 21.